Efficacy of Intravenous Fosfomycin in the Treatment of Complicated Urinary in Real-life Conditions.

Last updated: November 13, 2019
Sponsor: Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Overall Status: Active - Recruiting

Phase

N/A

Condition

Urinary Tract Infections

Treatment

N/A

Clinical Study ID

NCT04076436
FIS-FOS-2019-01
  • Ages > 18
  • All Genders

Study Summary

This will be a prospective observational multicentre study in real-life conditions of patients with complicated urinary infection of community presentation caused by Escherichia coli using intravenous fosfomycin, quinolones or beta-lactams.

It's a multicenter and multinational study and it will include 200 patients in the fosfomycin cohort and 200 patients in the control cohort (quinolones or beta-lactams).

Eligibility Criteria

Inclusion

Fosfomycin cohort:

  • Inclusion criteria: Patients over 18 years of age. Patients who have started treatmentwith intravenous fosfomycin, estimated that they will require at least 2 days oftreatment with fosfomycin, initiated as either as empirical treatment (within 24 hoursafter the emergency visit or onset of symptoms) or targeted treatment (within 24 hoursof the availability of the antibiogram).

Exclusion

  • Exclusion criteria: Patients under 18 years of age. Patients in palliative treatment. Control cohort (objective 1):

  • Inclusion criteria:Patients over 18 years of age. Patients who have started treatmentwith intravenous quinolones or beta-lactams, estimated that they will require at least 2 days of treatment with the drug, initiated as either as empirical treatment (within 24 hours after the emergency visit or onset of symptoms) or targeted treatment (within 24 hours of the availability of the antibiogram). Each patient from the fosfomycincohort will be matched with a patient from this control cohort according to their.

  • Exclusion criteria: Patients under 18 years of age.Patients in palliative treatment;Informed consent not signed by the patient.

Study Design

Total Participants: 400
Study Start date:
October 21, 2019
Estimated Completion Date:
December 31, 2021

Study Description

The objectives are:

  1. To asses the clinical and microbiological efficacy and safety of intravenous fosfomycin in the treatment of complicated urinary tract infections due to Escherichia coli in real life conditions, in comparison with a matched cohort of patients treated with quinolones or beta-lactams.

  2. To evaluate the frequency of microbiological failure and development of resistance (or decrease in sensitivity) in Escherichia coli isolates, depending on different pharmacokinetic and pharmacodynamic parameters, with special emphasis on fAUC0-24/MIC.

  3. To evaluate the frequency of microbiological failure and development of resistance (or decrease in sensitivity) and their association with the existence of basal mutations in genes related to intracellular transport or regulation of these transporters.

For objective 1, a study of prospective mated cohorts (fosfomycin cohort versus quinolones or beta-lactams cohort) will be performed, and for objectives 2 and 3 a prospective cohort study (fosfomycin cohort) will be conducted.

Connect with a study center

  • Hospital Universitario Reina Sofía

    Córdoba, 14004
    Spain

    Site Not Available

  • Hospital Universitario Virgen Macarena

    Sevilla, 41009
    Spain

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.